Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)

Ohad Hammer

View as an RSS Feed
View Ohad Hammer's Articles BY TICKER:
  • Lessons Learned From Sanofi-Aventis's Phase III Failure
    on Thu, Feb 3, 2011 • SNY • 7 Comments
  • Incyte: Myelofibrosis Drug Looks Promising
    on Mon, Dec 27, 2010 • INCY • Comment!
  • The Winner of ASH 2010: Seattle Genetics
    on Mon, Dec 20, 2010 • SGEN, CELG, GSK • 14 Comments
  • Synta's Lead Program Gains Momentum
    on Sun, Dec 5, 2010 • SNTA • 4 Comments
  • Promising Data Puts Exelixis Back on Track
    on Sun, Nov 28, 2010 • EXEL • 8 Comments
  • 3 Clear Winners of ESMO 2010
    on Mon, Oct 25, 2010 • ARQL, AVEO, DNDN • 9 Comments
  • Immunogen, Exelixis: Right Deals at the Right Time
    on Mon, Oct 11, 2010 • IMGN, EXEL • 3 Comments
  • Array Biopharma: A Wall Street Anomaly
    on Mon, Oct 4, 2010 • ARRY, AMGN, NVS • Comment!
  • Immunogen's T-DM1 Gets Presidential Treatment
    on Sun, Oct 3, 2010 • IMGN • Comment!
  • A Look at Immunogen Beyond the T-DM1 Setback
    on Fri, Sep 3, 2010 • IMGN, MITI, SGEN • 2 Comments
  • Immunogen: What Really Happened With T-DM1’s Filing?
    on Wed, Sep 1, 2010 • IMGN, RHHBY.OB • 9 Comments
  • Pfizer's Failure Provides Clarity for ArQule
    on Wed, Aug 25, 2010 • PFE, ARQL, DSKYY.PK • Comment!
  • Synta Is Heating Up
    on Mon, Aug 9, 2010 • SNTA, BMY, INFI • 6 Comments
  • Jury Still Out on Exelixis's Long Term Potential
    on Mon, Jul 26, 2010 • EXEL, BMY, GSK • 7 Comments
  • The Winner of ASCO 2010: Bristol Myers Squibb
    on Sun, Jul 4, 2010 • BMY • 3 Comments
  • How Array Got Its Groove Back
    on Wed, Apr 28, 2010 • ARRY, ARQL, EXEL • Comment!
  • Immunogen: Another Step Closer to FDA Approval
    on Wed, Apr 21, 2010 • IMGN, RHHBY.OB • 5 Comments
  • Arqule Joins the Phase III Club
    on Tue, Apr 13, 2010 • ARQL, EXEL • 4 Comments
  • Immunogen's Busy Month, Part II
    on Wed, Dec 2, 2009 • IMGN, MITI, SGEN • Comment!
  • Immunogen's Busy Month, Part I
    on Tue, Dec 1, 2009 • IMGN, SNY, GSK • 1 Comment
  • Incyte – Life After Debt (Part II)
    on Mon, Oct 19, 2009 • INCY, AZN, MRK • Comment!
  • Incyte: Life After Debt (Part I)
    on Wed, Oct 14, 2009 • INCY, IMGN, PFE • Comment!
  • Micromet: The Clock Is Ticking
    on Mon, Aug 24, 2009 • MITI, SNY, BMY • 1 Comment
  • Incyte Presents Investors with Unique Dilemmas
    on Mon, Aug 10, 2009 • INCY, AZN, CEPH • 1 Comment
  • Curagen: Positive Results at ASCO 2009
    on Tue, Jul 7, 2009 • CRGN, CLDX, SGEN • 2 Comments
  • Alimta: The 'Winner' of ASCO 2009
    on Tue, Jun 16, 2009 • LLY, RHHBY.OB, OSIP • 1 Comment
  • Top Biotech Picks for ASCO 2009 (Part II)
    on Wed, May 27, 2009 • SGEN, IMGN, MITI • 2 Comments
  • Top Biotech Picks for ASCO 2009 (Part I)
    on Wed, May 27, 2009 • PFE, CRGN, SGEN • 2 Comments
  • Micromet: More Reasons for Optimism
    on Mon, May 11, 2009 • MITI, EXEL, ARQL • 7 Comments
  • Bright Prospects for Micromet (Part 2)
    on Fri, Apr 24, 2009 • MITI, SNY, IMGN • 3 Comments
  • Bright Prospects for Micromet (Part 1)
    on Fri, Apr 24, 2009 • MITI, BYERF.PK, INFI • Comment!
  • Morphosys: A Biotech Rule Breaker (Part 2)
    on Mon, Mar 30, 2009 • MPHSF.PK, JNJ, AGN • Comment!